PTH(1-34) Analog (Generic Teriparatide)
Also known as: Teriparatide analog, PTH (1-34)
PTH(1-34) Analog (Generic Teriparatide), also called Teriparatide analog or PTH (1-34), is a PTH fragment in the PTH1 receptor agonist class. This entry covers generic and compounded preparations of the parathyroid hormone(1-34) fragment, the same active sequence as teriparatide.
For research use only.
Key Facts
- CAS
- 52232-67-4
- Molecular Weight (MW)
- ≈4118 g/mol
- Half-life
- ~1 h (sc); same as Forteo reference
- FDA status
- Not Approved
- Administration Route
- Subcutaneous
- Frequency
- —
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
- Targets
- PTH1 receptor
Research summary
PTH(1–34) analog class. The FDA-approved drug is teriparatide (Forteo/Bonsity). Research or compounded vials are not those products.
Peptide Library's PTH(1-34) Analog (Generic Teriparatide) profile summarises 3 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- Per local label or research protocol
- Frequency
- —
- Cycle
- —
- Administration Route
- Subcutaneous
- Reconstitution Guide
- —
- Timing Notes
- Used experimentally in bone-regeneration research.
Not yet checked against primary sources
These figures are compiled from earlier reference material. They have not been verified against FDA labelling, registered trials or published literature, no citation is attached to them, and none of them is a recommended dose. PTH(1-34) Analog (Generic Teriparatide) is queued for dosage evidence review.
Compare reported doses across the whole librarySequence & molecular data
| Molecular formula | C181H291N55O51S2 |
|---|---|
| Molecular weight | ≈4118 g/mol |
| CAS number | 52232-67-4 |
| Half-life | ~1 h (sc); same as Forteo reference |
| Appearance | White lyophilized powder or solution (compounding form) |
| Formulation | Lyophilized Powder |
| PubChem CID | 16133850 |
| FDA UNII | 10T9CSU89I |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
This entry covers generic and compounded preparations of the parathyroid hormone(1-34) fragment, the same active sequence as teriparatide. The pharmacology is the receptor biology of PTH1: intermittent daily exposure increases osteoblast number and survival and produces net bone formation, whereas continuous elevation shifts the balance toward RANKL-mediated osteoclastic resorption and bone loss. The distinction between the approved product and compounded material is not pharmacological but one of manufacturing, characterisation and regulatory oversight, and identity and purity of non-approved preparations are not assured.
Origin
Synthetic PTH(1–34).
Targets
Studies
- PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis (class-level)
- Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis (class-level)
- Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis (class-level)
Regulatory & research status
PTH(1-34) Analog (Generic Teriparatide) is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
Benefits
PTH(1-34) Analog (Generic Teriparatide) side effects
Side Effects
- Hypercalcemia
- Orthostasis
- Leg cramps
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
PTH(1-34) Analog (Generic Teriparatide): frequently asked questions
What is PTH(1-34) Analog (Generic Teriparatide)?
PTH(1–34) analog class. The FDA-approved drug is teriparatide (Forteo/Bonsity). Research or compounded vials are not those products.
How does PTH(1-34) Analog (Generic Teriparatide) work?
This entry covers generic and compounded preparations of the parathyroid hormone(1-34) fragment, the same active sequence as teriparatide. The pharmacology is the receptor biology of PTH1: intermittent daily exposure increases osteoblast number and survival and produces net bone formation, whereas continuous elevation shifts the balance toward RANKL-mediated osteoclastic resorption and bone loss.
Is PTH(1-34) Analog (Generic Teriparatide) FDA approved?
No. PTH(1-34) Analog (Generic Teriparatide) is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of PTH(1-34) Analog (Generic Teriparatide)?
Reported half-life for PTH(1-34) Analog (Generic Teriparatide) is ~1 h (sc); same as Forteo reference. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
What peptides are similar to PTH(1-34) Analog (Generic Teriparatide)?
Compounds most often compared with PTH(1-34) Analog (Generic Teriparatide) include Teriparatide, Abaloparatide, BPC-157 and Cardiogen. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Class-level evidence — PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis. Osteoporos Int, 2025External reference
- Class-level evidence — Clinical effects of teriparatide, abaloparatide, and romosozumab. J Bone Miner Metab, 2025External reference
- Class-level evidence — Effectiveness and Safety of Treatments to Prevent Fractures. Ann Intern Med, 2023External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 2
This PTH(1-34) Analog (Generic Teriparatide) profile is compiled from published literature (3 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track PTH(1-34) Analog (Generic Teriparatide) research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →